Page 8 - reflections_dyslipidaemia_newsletter7_2024

REFLECTIONS
Dyslipidaemia
Dyslipidaemia Global Newsletter #7 2024

The authors conclude that the attainment of recommended
CLINICAL PEARLS FROM THE FACULTY LDL-C targets through early and effective management of FH in
children and adolescents will probably require increased doses
Dyslipidaemia
and use of combination therapies. The combination of these
factors might reduce lifetime CV risk to become similar to people
in the general population.

WATCH
PROF. SANTOS DISCUSS THE
RELEVANCE OF THIS ARTICLE FOR CLICK HERE
CLINICAL PRACTICE. FOR THE LINK TO FULL ARTICLE

Obesity, dyslipidemia, and cardiovascular disease: A joint expert review from the

Obesity Medicine Association and the National Lipid Association 2024.
Bays HE, et al. J Clin Lipidol. 2024 Apr 18:S1933-2874(24)00048-5. doi: 10.1016/j.jacl.2024.04.001. Online ahead of print.

Obesity is a chronic disease affecting over 40% of adults in the US and nearly 2 billion adults worldwide. Obesity is associated with
increased risk of cardiovascular disease, substantially due to worsening of CVD risk factors that, in addition to high blood pressure,
high blood glucose, inflammation, and increased risk of thrombosis, includes an adiposopathic, atherogenic lipid pro- file.

The Obesity Medicine Association (OMA) and National Lipid Association (NLA) have provided a joint expert review on the
pathophysiological and clinical considerations regarding obesity, dyslipidaemia, and cardiovascular disease risk.

The OMA and NLA Joint expert review provided a summary of 10 sentinel take-away messages regarding the clinical management
of increased adiposity and dyslipidaemia.

Executive Clinical Summary – Obesity and Dyslipidaemia
1. The Obesity Medicine Association has defined obesity as 6. The mild to modest increase in blood LDL-C levels in
a: “serious, chronic, progressive, relapsing, and treatable patients with obesity may not adequately characterize the
multifactorial, neurobehavioral disease, wherein an increased ASCVD risk attributable to dyslipidaemia.
increase in adiposity promotes adipose tissue dysfunction 7. Among patients with increased adiposity, healthful
and abnormal fat mass physical forces, resulting in nutrition and routine physical activity may help reduce
adverse metabolic, biomechanical, and psychosocial body weight and improve lipid levels.
health consequences.” 8. Among patients with increased adiposity, weight reduction
2. In white adipocytes, triglycerides make up over 90% of of ≥5% may reduce blood triglyceride levels, with greater
adipocyte volume. weight reduction further reducing blood triglyceride levels
3. Adipose tissue represents the largest body reservoir for and increasing blood HDL-C levels; even greater weight
free cholesterol. reduction of >10–15% has the potential to reduce CVD
4. Most of the lipids in adipose tissue are derived from risk.
interactions with circulating lipoproteins. 9. Among patients with increased adiposity, weight reduction
5. Among patients with increased adiposity, a commonly typically results in only mild-to-modest reductions in blood
described lipid pattern is adiposopathic dyslipidaemia LDL-C levels.
(“atherogenic dyslipidaemia”) that includes elevated blood 10. Among patients with increased adiposity, treatment
triglyceride levels, reduced blood HDL-C levels, increased strategies to reduce CVD risk include evidenced-based
non-HDL-C, elevated apolipoprotein B, increased LDL therapies that concurrently facilitate weight reduction and
particle number, and increased small dense LDL particles. atherogenic lipid lowering.

TABLE OF CONTENTS